Several years ago, we demonstrated that GI tumor cells were killed by the multi-kinase inhibitor sorafenib combined with the HDAC inhibitors vorinostat or sodium valproate, in part, via CD95 death receptor signalling and autophagosome formation; this data was translated into two clinical trials (; ). Here, HDAC9 is linked to neoplasm.